In Advertising of medicines

Enter a keyword or phrase to search all pages in this section:


Advanced search

Archive:

Looking for a previously published document in this section?

Advertising investigations

The MHRA's policy is to publish a report of the outcome of investigations into complaints about advertising for licensed medicines, to inform stakeholders and the public. It will supplement the actions already taken to alert health professionals and the public to misleading advertising such as the publication of a corrective statement where a serious risk to public health is perceived. All complaints received from 1 December 2003 will be published here.

We also publish reports of actions taken in cases where advertisements have been identified through MHRA monitoring of published advertising.

The publication of a summary reports is intended to provide guidance to advertisers on how the Regulations are interpreted and also act as an information resource for advertisers, consumers and the media on decision making and actions taken by the MHRA in advertising casework. This has a number of potential benefits including improved compliance with the Regulations.

Results of investigations
The results of our investigations since 1 December 2003 are below.

Contacts for further information
Anyone who has concerns about misleading advertising of medicines should contact the MHRA Advertising Unit, 14-112, Market Towers, Vauxhall, London SW8 5NQ. Alternatively, contact the pharmaceutical self-regulatory bodies, the Proprietary Association of Great Britain (PAGB) for advertising for over the counter medicines, or the Prescription Medicines Code of Practice Authority (PMCPA) for advertisements to health professionals for prescription medicines.


Page last modified: 16 November 2007